Immunome (IMNM) Profit After Tax: 2023-2025
Historic Profit After Tax for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$57.5 million.
- Immunome's Profit After Tax fell 21.99% to -$57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$222.7 million, marking a year-over-year increase of 27.05%. This contributed to the annual value of -$293.0 million for FY2024, which is 174.29% down from last year.
- As of Q3 2025, Immunome's Profit After Tax stood at -$57.5 million, which was down 32.40% from -$43.4 million recorded in Q2 2025.
- Immunome's 5-year Profit After Tax high stood at -$4.3 million for Q1 2023, and its period low was -$129.5 million during Q1 2024.
- Moreover, its 3-year median value for Profit After Tax was -$43.4 million (2025), whereas its average is -$49.3 million.
- In the last 5 years, Immunome's Profit After Tax slumped by 2,932.60% in 2024 and then soared by 67.84% in 2025.
- Immunome's Profit After Tax (Quarterly) stood at -$92.6 million in 2023, then increased by 13.37% to -$80.2 million in 2024, then decreased by 21.99% to -$57.5 million in 2025.
- Its last three reported values are -$57.5 million in Q3 2025, -$43.4 million for Q2 2025, and -$41.6 million during Q1 2025.